Prognostic Role Of Computed Tomography Textural Features In Early-Stage Non-Small Cell Lung Cancer Patients Receiving Stereotactic Body Radiotherapy

References

• Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010;303(11):1070–1076. doi:10.1001/jama.2010.26120233825
   PubMed Web of Science ®Google Scholar
• Howington JA, Blum MG, Chang AC, Balekian AA, Murthy SC. Treatment of stage I and II non-small cell lung cancer. Chest. 2013;143(5):e278S–e313S. doi:10.1378/chest.12-235923649443
   PubMedGoogle Scholar
• Nanda RH, Liu Y, Gillespie TW, et al. Stereotactic body radiation therapy versus no treatment for early stage non-small cell lung cancer in medically inoperable elderly patients: a national cancer data base analysis. Cancer. 2015;121(23):4222–4230. doi:10.1002/cncr.2964026348268
   PubMed Web of Science ®Google Scholar
• Spratt DE, Wu AJ, Adeseye V, et al. Recurrence patterns and second primary lung cancers after stereotactic body radiation therapy for early-stage non-small-cell lung cancer: implications for surveillance. Clin Lung Cancer. 2016;17(3):177–183. doi:10.1016/j.cllc.2015.09.00626602271
   PubMed Web of Science ®Google Scholar
• Kann BH, Miccio JA, Stahl JM, et al. Stereotactic body radiotherapy with adjuvant systemic therapy for early-stage non-small cell lung carcinoma: a multi-institutional analysis. Radiother Oncol. 2019;132:188–196. doi:10.1016/j.radonc.2018.10.01730391106
   PubMed Web of Science ®Google Scholar
• Verma V, Cushman TR, Selek U, Tang C, Welsh JW. Safety of combined immunotherapy and thoracic radiation therapy: analysis of 3 single-institutional phase I/II trials. Int J Radiat Oncol Biol Phys. 2018;101(5):1141–1148. doi:10.1016/j.ijrobp.2018.04.05430012526
   PubMed Web of Science ®Google Scholar
• Huang K, Senthi S, Palma DA, et al. High-risk CT features for detection of local recurrence after stereotactic ablative radiotherapy for lung cancer. Radiother Oncol. 2013;109(1):51–57. doi:10.1016/j.radonc.2013.06.04723953413
   PubMed Web of Science ®Google Scholar
• Na F, Wang J, Li C, Deng L, Xue J, Lu Y. Primary tumor standardized uptake value measured on F18-fluorodeoxyglucose positron emission tomography is of prediction value for survival and local control in non–small-cell lung cancer receiving radiotherapy: meta-analysis. J Thorac Oncol. 2014;9(6):834–842. doi:10.1097/JTO.000000000000018524787963
   PubMed Web of Science ®Google Scholar
• Kwon W, Howard BA, Herndon JE, Patz EF. FDG uptake on positron emission tomography correlates with survival and time to recurrence in patients with stage I non-small-cell lung cancer. J Thorac Oncol. 2015;10(6):897–902. doi:10.1097/JTO.000000000000053425811445
   PubMed Web of Science ®Google Scholar
• Hoang JK, Hoagland LF, Coleman RE, Coan AD, Herndon JE, Patz EF. Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non–small-cell lung carcinoma. J Clin Oncol. 2008;26(9):1459–1464. doi:10.1200/JCO.2007.14.362818349396
   PubMed Web of Science ®Google Scholar
• Agarwal M, Brahmanday G, Bajaj SK, Ravikrishnan KP, Wong C-YO. Revisiting the prognostic value of preoperative (18)F-fluoro-2-deoxyglucose ((18)F-FDG) positron emission tomography (PET) in early-stage (I & II) non-small cell lung cancers (NSCLC). Eur J Nucl Med Mol Imaging. 2010;37(4):691–698. doi:10.1007/s00259-009-1291-x19915840
   PubMed Web of Science ®Google Scholar
• Mattonen SA, Palma DA, Haasbeek CJ, Senan S, Ward AD. Early prediction of tumor recurrence based on CT texture changes after stereotactic ablative radiotherapy (SABR) for lung cancer. Med Phys. 2014;41(3):033502. doi:10.1118/1.486621924593744
   PubMed Web of Science ®Google Scholar
• Fried DV, Mawlawi O, Zhang L, et al. Stage III non–small cell lung cancer: prognostic value of FDG PET quantitative imaging features combined with clinical prognostic factors. Radiology. 2016;278(1):214–222. doi:10.1148/radiol.201514292026176655
   PubMed Web of Science ®Google Scholar
• Lovinfosse P, Janvary ZL, Coucke P, et al. FDG PET/CT texture analysis for predicting the outcome of lung cancer treated by stereotactic body radiation therapy. Eur J Nucl Med Mol Imaging. 2016;43(8):1453–1460. doi:10.1007/s00259-016-3314-826830299
   PubMed Web of Science ®Google Scholar
• Aerts HJ, Velazquez ER, Leijenaar RT, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun. 2014;5:4006. doi:10.1038/ncomms500624892406
   PubMed Web of Science ®Google Scholar
• van Timmeren JE, van Elmpt W, Leijenaar RTH, et al. Longitudinal radiomics of cone-beam CT images from non-small cell lung cancer patients: evaluation of the added prognostic value for overall survival and locoregional recurrence. Radiother Oncol. 2019;136:78–85. doi:10.1016/j.radonc.2019.03.03231015133
   PubMed Web of Science ®Google Scholar
• Dennie C, Thornhill R, Souza CA, et al. Quantitative texture analysis on pre-treatment computed tomography predicts local recurrence in stage I non-small cell lung cancer following stereotactic radiation therapy. Quant Imaging Med Surg. 2017;7(6):614–622. doi:10.21037/qims29312866
   PubMed Web of Science ®Google Scholar
• Andratschke N, Zimmermann F, Boehm E, et al. Stereotactic radiotherapy of histologically proven inoperable stage I non-small cell lung cancer: patterns of failure. Radiother Oncol. 2011;101(2):245–249. doi:10.1016/j.radonc.2011.06.00921724287
   PubMed Web of Science ®Google Scholar
• Huynh E, Coroller TP, Narayan V, et al. CT-based radiomic analysis of stereotactic body radiation therapy patients with lung cancer. Radiother Oncol. 2016;120(2):258–266. doi:10.1016/j.radonc.2016.05.02427296412
   PubMed Web of Science ®Google Scholar
• Chi A, Wen S, Liao Z, et al. What would be the most appropriate alpha/beta ratio in the setting of stereotactic body radiation therapy for early stage non-small cell lung cancer. Biomed Res Int. 2013;2013:391021. doi:10.1155/2013/39102124350266
   PubMed Web of Science ®Google Scholar
• Onishi H, Shirato H, Nagata Y, et al. Hypofractionated stereotactic radiotherapy (hypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a japanese multi-institutional study. J Thorac Oncol. 2007;2(7):S94–S100. doi:10.1097/JTO.0b013e318074de3417603311
   PubMed Web of Science ®Google Scholar
• Pyka T, Bundschuh RA, Andratschke N, et al. Textural features in pre-treatment [F18]-FDG-PET/CT are correlated with risk of local recurrence and disease-specific survival in early stage NSCLC patients receiving primary stereotactic radiation therapy. Radiat Oncol. 2015;10:100. doi:10.1186/s13014-015-0407-725900186
   PubMed Web of Science ®Google Scholar
• Dong X, Sun X, Sun L, et al. Early change in metabolic tumor heterogeneity during chemoradiotherapy and its prognostic value for patients with locally advanced non-small cell lung cancer. PLoS ONE. 2016;11(6):e0157836. doi:10.1371/journal.pone.015783627322376
   PubMed Web of Science ®Google Scholar
• Li Q, Kim J, Balagurunathan Y, et al. CT imaging features associated with recurrence in non-small cell lung cancer patients after stereotactic body radiotherapy. Radiat Oncol. 2017;12(1):158. doi:10.1186/s13014-017-0892-y28946909
   PubMedGoogle Scholar
• Trovo M, Linda A, El Naqa I, Javidan-Nejad C, Bradley J. Early and late lung radiographic injury following stereotactic body radiation therapy (SBRT). Lung Cancer. 2010;69(1):77–85. doi:10.1016/j.lungcan.2009.09.00619910075
   PubMed Web of Science ®Google Scholar
• Palma DA, Senan S, Haasbeek CJA, Verbakel WFAR, Vincent A, Lagerwaard F. Radiological and clinical pneumonitis after stereotactic lung radiotherapy: a matched analysis of three-dimensional conformal and volumetric-modulated arc therapy techniques. Int J Radiat Oncol Biol Phys. 2011;80(2):506–513. doi:10.1016/j.ijrobp.2010.02.03220584582
   PubMed Web of Science ®Google Scholar
• Videtic GMM, Stitt LW, Dar AR, et al. Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for limited-stage small-cell lung cancer is associated with decreased survival. J Clin Oncol. 2003;21(8):1544–1549. doi:10.1200/JCO.2003.10.08912697879
   PubMed Web of Science ®Google Scholar
• Fischer-Valuck BW, Durci M, Katz SR, et al. Influence of patient characteristics on survival following treatment with helical stereotactic body radiotherapy (SBRT) in stage I non-small-cell lung cancer. Thorac Cancer. 2013;4(1):27–34. doi:10.1111/j.1759-7714.2012.00137.x28920325
   PubMed Web of Science ®Google Scholar
• Miller CJ, Martin B, Stang K, et al. Predictors of distant failure after stereotactic body radiation therapy for stages I to IIA non-small-cell lung cancer. Clin Lung Cancer. 2019;20(1):37–42. doi:10.1016/j.cllc.2018.09.00230279109
   PubMed Web of Science ®Google Scholar
• Clarke K, Taremi M, Dahele M, et al. Stereotactic body radiotherapy (SBRT) for non-small cell lung cancer (NSCLC): is FDG-PET a predictor of outcome? Radiother Oncol. 2012;104(1):62–66. doi:10.1016/j.radonc.2012.04.01922682749
   PubMed Web of Science ®Google Scholar
• Takeda A, Sanuki N, Fujii H, et al. Maximum standardized uptake value on FDG-PET is a strong predictor of overall and disease-free survival for non small-cell lung cancer patients after stereotactic body radiotherapy. J Thorac Oncol. 2014;9(1):65–73. doi:10.1097/JTO.000000000000003124346094
   PubMed Web of Science ®Google Scholar
• Tanaka H, Hayashi S, Hoshi H. Pretreatment maximum standardized uptake value on 18F-fluorodeoxyglucose positron emission tomography is a predictor of outcome for stage I non-small cell lung cancer after stereotactic body radiotherapy. Asia Pac J Clin Oncol. 2016;12(1):e113–117. doi:10.1111/ajco.1212824176011
   PubMed Web of Science ®Google Scholar
• Li Q, Kim J, Balagurunathan Y, et al. Imaging features from pretreatment CT scans are associated with clinical outcomes in nonsmall-cell lung cancer patients treated with stereotactic body radiotherapy. Med Phys. 2017;44(8):4341–4349. doi:10.1002/mp.2017.44.issue-828464316
   PubMed Web of Science ®Google Scholar
• Zwanenburg ALS, Vallières M, Löck S Image biomarker standardisation initiative. arXiv preprint arXiv:161207003.
   Google Scholar
• Zwanenburg A. Radiomics in nuclear medicine: robustness, reproducibility, standardization, and how to avoid data analysis traps and replication crisis. Eur J Nucl Med Mol Imaging. 2019. doi:10.1007/s00259-019-04391-8
   PubMed Web of Science ®Google Scholar
• Chen Y, Guo W, Lu Y, Zou B. Dose-individualized stereotactic body radiotherapy for T1-3N0 non-small cell lung cancer: long-term results and efficacy of adjuvant chemotherapy. Radiother Oncol. 2008;88(3):351–358. doi:10.1016/j.radonc.2008.07.01318722684
   PubMed Web of Science ®Google Scholar
• Bernstein MB, Krishnan S, Hodge JW, Chang JY. Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach? Nat Rev Clin Oncol. 2016;13(8):516–524. doi:10.1038/nrclinonc.2016.3026951040
   PubMed Web of Science ®Google Scholar
• Nyman J, Hallqvist A, Lund JA, et al. SPACE - A randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC. Radiother Oncol. 2016;121(1):1–8. doi:10.1016/j.radonc.2016.08.01527600155
   PubMed Web of Science ®Google Scholar